Research Title: A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab in Patients with Diabetic Macular Edema (Pagoda)
Sponsor: Hoffmann-La Roche
Principal Investigator: Robert Stoltz, M.D., Ph.D.
Description: This study will evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab (PDS) in Participants with Diabetic Macular Edema (DME) when treated every 24 weeks (Q24W) compared with intravitreal ranibizumab 0.5 mg every 4 weeks (Q4W).
Start Date: November 2019
Recruitment: Enrolling
Project Personnel: Leslie Marcus, CCRC; Caitlin Harrison, CCRC, COA; Stephanie Campbell, CRC, COA; Amber Adams, CRC, COA
Location(s): Marietta; 833 Campbell Hill Street, Suite 300, Marietta, GA 30060
Clinical Trial Team
Active Trials
Past Trials
- AART C-02-60
- Acucela 4429-202 SEATTLE
- Aerpio AKB-9778-CI-5001 TIME-2b
- Allergan 150998-005 CEDAR
- Allergan 1771-201-008 MAPLE
- Allergan 190342-038 BEACON
- ALLERGAN 206207-012
- AREDS2
- AREDS2 ForeseeHome
- Blair Symington
- C-09-067 RACE
- DRCR.net Protocol N
- Gemini GEM-NH-002 Clarity 2
- Genentech GR39821
- Graybug GBV-102-002 Altissimo
- HORIZON FVF3426g
- KalVista KVD011-201
- LFG316A2203
- MARINA FVF2598g
- Novartis CSPP100A2244
- Ocriplasmin Research to Better Inform Treatment (ORBIT)
- OPH1002
- OPH1004
- Ophthotech OPH2003
- PDEX
- Regeneron R2176-3-AMD-1417 CAPELLA
- Regeneron R910-3-AMD-1517 ONYX
- Regeneron R910-3-DME-1518 RUBY
- Regeneron VGFTe-OD-1411 PANORAMA
- RIDE FVF4168g
- RISE FVF4170g
- Roche BP 30099 BOULEVARD
- Roche BP29647 AVENUE
- Roche GX29176 CHROMA
- Roche GX30191 OMASPECT
- SAILOR FVF3689g
- SCORE
- SCORE2
- Shelby Satterwhite
- Suprachoroidal Buckling for Retinal Detachment
- Taiwan Liposome Company (TLC) TLC399A2002
- Xcenda C-01-17 ForeseeHome